Showing results (1871-1880 of 1,996) with videos related to

Sort By:
Pageof 200
The Lancet. Neurology|March 20, 2021
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trialJohn W Day, Richard S Finkel, Claudia A Chiriboga, et al.
The Lancet. Neurology|December 23, 2021
Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trialEugenio Mercuri, Nicolas Deconinck, Elena S Mazzone, et al.
The Lancet. Neurology|September 17, 2022
Carotid endarterectomy or stenting or best medical treatment alone for moderate-to-severe asymptomatic carotid artery stenosis: 5-year results of a multicentre, randomised controlled trialTilman Reiff, Hans-Henning Eckstein, Ulrich Mansmann, et al.
The Lancet. Neurology|October 22, 2021
Amantadine in the treatment of Parkinson's disease and other movement disordersOlivier Rascol, Margherita Fabbri, Werner Poewe
The Lancet. Neurology|October 23, 2021
Neocortical development and epilepsy: insights from focal cortical dysplasia and brain tumoursIngmar Blumcke, Silvia Budday, Annapurna Poduri, et al.
The Lancet. Neurology|October 23, 2021
The role of manganese dysregulation in neurological disease: emerging evidenceDimitri Budinger, Serena Barral, Audrey K S Soo, et al.
The Lancet. Neurology|February 19, 2022
Whole genome sequencing for the diagnosis of neurological repeat expansion disorders in the UK: a retrospective diagnostic accuracy and prospective clinical validation studyKristina Ibañez, James Polke, R Tanner Hagelstrom, et al.
The Lancet. Neurology|February 19, 2022
Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation studyPascal Benkert, Stephanie Meier, Sabine Schaedelin, et al.
The Lancet. Neurology|February 19, 2022
Advances and controversies in frontotemporal dementia: diagnosis, biomarkers, and therapeutic considerationsBradley F Boeve, Adam L Boxer, Fiona Kumfor, et al.
The Lancet. Neurology|April 15, 2019
CSF and blood biomarkers for Parkinson's diseaseLucilla Parnetti, Lorenzo Gaetani, Paolo Eusebi, et al.
Pageof 200